Early Rash Development May Signal Superior Benefit With Lapatinib

Early development of rash identified patients with HER2-positive early breast cancer who received superior benefit from lapatinib-based therapy.

Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer - ScienceDirect

Cancers, Free Full-Text

Frontiers Immune Checkpoint Inhibitors in Triple Negative Breast

Targeted therapeutic options and future perspectives for HER2-positive breast cancer

PDF) Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis

Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy

Cutaneous responses in HER2+ metastatic breast cancer: A retrospective case series of a Phase 1b study of Tucatinib, an Oral HER2-specific inhibitor in combination with Capecitabine and/or Trastuzumab in third-line or later

PDF) Lapatinib plus Letrozole as First-Line Therapy for HER-2

Prognostic value of early rash in all lapatinib-containing treatment arms*